X4 Pharmaceuticals (XFOR) Competitors $1.52 +0.05 (+3.40%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.04 (+2.57%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR vs. OKUR, MAAQ, KZR, RNTX, CALC, ESLA, SCYX, SNYR, FGEN, and CLNNShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), CalciMedica (CALC), Estrella Immunopharma (ESLA), SCYNEXIS (SCYX), Synergy CHC (SNYR), FibroGen (FGEN), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. X4 Pharmaceuticals vs. Its Competitors OnKure Therapeutics Mana Capital Acquisition Kezar Life Sciences Rein Therapeutics CalciMedica Estrella Immunopharma SCYNEXIS Synergy CHC FibroGen Clene X4 Pharmaceuticals (NASDAQ:XFOR) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment. Is XFOR or OKUR more profitable? X4 Pharmaceuticals has a net margin of 46.54% compared to OnKure Therapeutics' net margin of 0.00%. OnKure Therapeutics' return on equity of -49.13% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets X4 Pharmaceuticals46.54% -181.56% -54.36% OnKure Therapeutics N/A -49.13%-45.72% Does the media refer more to XFOR or OKUR? In the previous week, X4 Pharmaceuticals had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 2 mentions for X4 Pharmaceuticals and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.87 beat X4 Pharmaceuticals' score of 1.31 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment X4 Pharmaceuticals Positive OnKure Therapeutics Very Positive Do analysts rate XFOR or OKUR? X4 Pharmaceuticals currently has a consensus target price of $72.33, indicating a potential upside of 4,658.77%. OnKure Therapeutics has a consensus target price of $32.33, indicating a potential upside of 1,198.53%. Given X4 Pharmaceuticals' higher probable upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than OnKure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Do institutionals & insiders have more ownership in XFOR or OKUR? 72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 2.2% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, XFOR or OKUR? X4 Pharmaceuticals has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX4 Pharmaceuticals$31.36M0.28-$37.45M$2.140.71OnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.47 Which has more risk and volatility, XFOR or OKUR? X4 Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. SummaryX4 Pharmaceuticals and OnKure Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.80M$2.93B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E Ratio0.7120.5028.6119.73Price / Sales0.28267.14411.30174.40Price / CashN/A43.1536.0257.96Price / Book0.397.768.235.67Net Income-$37.45M-$55.11M$3.23B$257.79M7 Day Performance-8.43%0.96%0.01%0.54%1 Month Performance-44.32%8.45%5.63%8.86%1 Year Performance-93.33%-2.37%26.55%14.22% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.9221 of 5 stars$1.52+3.4%$72.33+4,658.8%-93.1%$8.80M$31.36M0.7180Positive NewsGap UpHigh Trading VolumeOKUROnKure Therapeutics3.5906 of 5 stars$2.50flat$32.33+1,193.3%N/A$33.78MN/A-0.48N/APositive NewsMAAQMana Capital AcquisitionN/A$4.15-3.3%N/A+657.3%$33.72MN/A0.001KZRKezar Life Sciences4.1823 of 5 stars$4.58+1.6%$39.50+762.4%-27.2%$33.48M$7M-0.4260News CoveragePositive NewsAnalyst ForecastRNTXRein TherapeuticsN/A$1.50+4.2%N/AN/A$33.23MN/A-0.529Positive NewsGap DownCALCCalciMedica2.8698 of 5 stars$2.32+16.0%$16.00+589.7%-57.4%$32.41MN/A-1.4930Gap UpHigh Trading VolumeESLAEstrella Immunopharma3.1247 of 5 stars$0.89+0.6%$16.00+1,707.9%-44.3%$32.01MN/A-3.40N/ASCYXSCYNEXIS1.0662 of 5 stars$0.82+16.5%N/A-65.1%$31.96M$2.63M-1.4660Positive NewsHigh Trading VolumeSNYRSynergy CHC3.9044 of 5 stars$3.39+9.0%$10.00+195.0%N/A$31.15M$34.83M0.0040Gap UpFGENFibroGen4.6966 of 5 stars$7.69+7.6%$250.00+3,151.0%-72.4%$31.07M$29.62M-3.08570Positive NewsCLNNClene3.575 of 5 stars$3.73+3.9%$40.00+972.4%-26.0%$30.85M$340K-0.92100 Related Companies and Tools Related Companies OKUR Competitors MAAQ Competitors KZR Competitors RNTX Competitors CALC Competitors ESLA Competitors SCYX Competitors SNYR Competitors FGEN Competitors CLNN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XFOR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XFOR Stock Alerts